<- Go Home
NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Market Cap
$33.8M
Volume
280.5K
Cash and Equivalents
$666.0K
EBITDA
-$8.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$2.60
52 Week Low
$0.68
Dividend
N/A
Price / Book Value
-48.35
Price / Earnings
-2.70
Price / Tangible Book Value
-48.35
Enterprise Value
$33.1M
Enterprise Value / EBITDA
-3.87
Operating Income
-$8.6M
Return on Equity
779.30%
Return on Assets
-303.90
Cash and Short Term Investments
$666.0K
Debt
N/A
Equity
-$519.0K
Revenue
N/A
Unlevered FCF
-$6.6M
Sector
Biotechnology
Category
N/A